C4B Gene

Introduction

The C4B gene (Complement Component 4B) encodes a crucial protein in the complement cascade, sharing significant sequence similarity with its close relative C4A while exhibiting distinct biochemical properties and disease associations. Located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, C4B is essential for immune defense, inflammation regulation, and increasingly recognized for its role in neurobiology and neurodegenerative diseases^{1Schizophrenia risk from complex variation of complement component 42016 · Nature · DOI 10.1038/nature16549 · PMID 26898108Open reference2C4 in brain: implications for understanding synaptic remodeling and schizophrenia2019 · Neurochemical Research · DOI 10.1007/s11064-019-02852-w · PMID 31701302Open reference}. Unlike C4A, which preferentially binds amino groups, C4B shows higher affinity for hydroxyl groups on target surfaces, leading to different functional outcomes in complement activation and immune complex handling. Research has revealed important roles for C4B in Alzheimer’s disease susceptibility, autoimmune conditions, and neurodevelopmental processes, making it a significant gene for understanding immune-brain interactions in disease.

Gene Overview

Protein Structure and Function

Protein Architecture

C4B encodes complement component 4B, a 1741-amino acid zymogen structurally similar to C4A. The protein is composed of three polypeptide chains:

• α-chain (104 kDa): Contains the thioester bond critical for covalent attachment to surfaces. The thioester in C4B preferentially reacts with hydroxyl groups, unlike C4A which prefers amino groups

• β-chain (75 kDa): Provides structural stability in circulation

• γ-chain (28 kDa): C-terminal fragment generated upon activation

The structural similarity between C4A and C4B (approximately 99% sequence identity in the coding region) reflects their shared evolutionary origin and overlapping functions, yet their distinct thioester reactivity determines their unique roles in immune surveillance and disease pathogenesis.

Biochemical Properties

The key difference between C4A and C4B lies in their thioester chemistry:

1. C4B reactivity: Preferentially binds hydroxyl groups (sugars, carbohydrates) on microbial surfaces

2. C4A reactivity: Preferentially binds amino groups (proteins) on immune complexes

3. Functional implications: C4B is more effective at opsonizing bacteria and foreign particles, while C4A is more efficient at clearing immune complexes

This biochemical distinction has important implications for understanding their differential disease associations.

Complement Pathway Functions

C4B participates in multiple complement activation pathways:

1. Classical pathway: Activated by C1 complex (C1q:C1r:C1s) binding to antibodies or pathogen surfaces

2. Lectin pathway: Activated by mannose-binding lectin (MBL) and ficolins

3. Terminal pathway: C4b contributes to C5 convertase formation and membrane attack complex (MAC) assembly

Cleavage products include:

• C4a: Anaphylatoxin that triggers inflammation, histamine release, and immune cell recruitment

• C4b: Opsonin that covalently attaches to pathogen surfaces, facilitating phagocytosis

Role in Neurodegeneration

Alzheimer’s Disease

C4B has been increasingly implicated in Alzheimer’s disease pathogenesis through several mechanisms:

Complement Activation in AD Brain

Elevated C4B expression has been documented in AD brains, particularly in regions affected by amyloid pathology^{3Complement component 4 is increased in Alzheimer's disease brains2020 · Molecular Neurobiology · DOI 10.1007/s12035-020-02013-1 · PMID 32623665Open reference}. Studies using proteomic analysis of AD brain tissue have identified significant upregulation of complement components, including C4B, in the prefrontal cortex and hippocampus of AD patients compared to age-matched controls^{4Large-scale proteomic analysis of Alzheimer's disease brain identifies altered complement pathway2019 · Acta Neuropathologica Communications · PMID 31847895Open reference}.

Key mechanisms include:

• Amyloid plaque opsonization: C4b can bind to amyloid-beta (Aβ) plaques, marking them for microglial clearance

• Chronic inflammation: C4B contributes to the neuroinflammatory environment that drives disease progression

• Synaptic elimination: C4B-mediated complement activation tags synapses for microglial phagocytosis

Genetic Associations

Genetic studies have identified associations between C4B variants and AD risk:

• C4B deficiency: Some studies suggest C4B deficiency is associated with increased AD risk^{5C4B deficiency is associated with increased risk of Alzheimer's disease2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-121714 · PMID 23531557Open reference}

• Copy number variation: C4B CNV has been linked to disease susceptibility

• Haplotype effects: Specific C4B haplotypes show differential association with AD

The relationship between C4B and AD appears to be complex, with both protective and risk-associated variants identified in different populations.

Microglial Activation

C4B serves as a critical signal for microglial activation in the AD brain^{6Microglial dynamics in Alzheimer's disease2020 · Progress in Brain Research · PMID 32888823Open reference}:

• C4b acts as a “find me” signal, attracting microglia to sites of pathology

• Microglial complement receptors (CR3) recognize C4b-coated targets

• This interaction promotes phagocytosis while also driving inflammatory cytokine release

Parkinson’s Disease

In Parkinson’s disease, C4B contributes to:

1. Dopaminergic neuron vulnerability: Inflammatory signaling exacerbates loss of neurons in the substantia nigra

2. Microglial activation: Sustained C4B-mediated complement activation in PD brains

3. α-synuclein pathology: C4B may interact with α-synuclein aggregates, potentially accelerating pathological spread

Post-mortem studies show increased C4B expression in the substantia nigra of PD patients, correlating with disease severity^{7Complement activation in Alzheimer's disease: therapeutic targeting2023 · Nature Reviews Neurology · PMID 37612438Open reference}.

Autism Spectrum Disorder

C4B copy number variation has been studied in autism spectrum disorder (ASD):

• Copy number association: Some studies link C4B copy number to ASD risk

• Synaptic pruning: Altered C4B activity during neurodevelopment may affect synaptic pruning

• Immune dysregulation: Complement abnormalities may contribute to immune-related mechanisms in ASD

The relationship between C4B and ASD involves complex gene-environment interactions during critical periods of brain development.

Multiple Sclerosis

C4A and C4B show opposing roles in multiple sclerosis^{8Opposing roles of C4A and C4B in multiple sclerosis2015 · Nature Reviews Neurology · DOI 10.1038/nrneurol.2015.216 · PMID 26515041Open reference}:

• C4B appears pathogenic: Higher C4B expression is associated with disease progression

• C4A appears protective: Higher C4A may be beneficial

• Mechanism: Differential roles in demyelination and remyelination processes

This dichotomy provides valuable insights into complement-mediated neuroinflammation and suggests that targeting specific complement components may have therapeutic value.

Autoimmune Disease Associations

Systemic Lupus Erythematosus (SLE)

C4B, like C4A, is strongly associated with systemic lupus erythematosus:

C4B Deficiency

• Genetic deficiency: Complete C4B deficiency (homozygous null alleles) is a significant genetic risk factor for SLE

• Immune complex clearance: C4B deficiency impairs clearance of apoptotic cells and immune complexes

• Autoantibody formation: Reduced complement activity leads to accumulation of self-antigens

Phenotypic Differences

• C4A vs C4B deficiency may present with different clinical features

• C4B deficiency often associated with different autoantibody patterns

• Some SLE patients have isolated C4B deficiency without C4A deficiency

Disease Mechanisms

The complement system is essential for:

• Clearance of apoptotic cell debris

• Processing and clearance of immune complexes

• Prevention of autoantibody formation against self-antigens

Other Autoimmune Conditions

C4B variants have been associated with:

• Rheumatoid arthritis: Altered complement activation

• Type 1 diabetes: Complement-mediated β-cell destruction

• Sjögren’s syndrome: Immune complex deposition

Expression Pattern

Brain Expression

C4B is expressed in multiple cell types within the central nervous system:

Peripheral Expression

C4B is highly expressed in:

• Liver: Primary site of complement protein synthesis (hepatocytes)

• Spleen: Immune cell production

• Kidney: Local complement production

• Lung: Mucosal immune defense

Plasma Levels

C4B contributes to total plasma C4 levels:

• Normal range: 0.2-0.5 g/L (combined C4)

• Elevated in inflammation

• Decreased in complement deficiency states

Genetic Variation

Copy Number Variation

The C4B gene shows extensive copy number variation:

• 1-6 copies per diploid genome

• Higher copy numbers generally correlate with higher expression

• CNV associated with schizophrenia, AD, and autoimmune disease risk

Single Nucleotide Polymorphisms

Key SNPs in the C4B region:

• Functional variants: Affect thioester reactivity and binding preferences

• Regulatory variants: Influence expression levels

• Disease-associated variants: Linked to AD, SLE, and MS risk

Gene Structure

The C4B gene spans approximately 21 kb and contains:

• 41 exons

• Alternative splicing variants

• MHC class III regulatory elements

Protein Interactions

Therapeutic Implications

Complement Inhibition

Targeting C4B-mediated pathways represents a therapeutic strategy for:

1. Neurodegenerative diseases: Modulating neuroinflammation

2. Autoimmune conditions: Reducing pathogenic complement activation

3. Transplantation: Preventing complement-mediated tissue damage

Challenges

• Immune defense: Complement inhibition increases infection risk

• Specificity: Targeting C4B specifically while preserving C4A function

• Timing: Early intervention may be critical for efficacy

Current Research

Clinical trials are evaluating complement inhibitors for:

• Alzheimer’s disease

• Multiple sclerosis

• Systemic lupus erythematosus

Research Methods

Experimental Approaches

• Genetic studies: GWAS, exome sequencing, CNV analysis

• Proteomics: Quantification of C4B in brain tissue and CSF

• Functional studies: In vitro complement activation assays

• Animal models: C4B knockout and transgenic mice

Biomarkers

C4B levels may serve as:

• Disease progression marker

• Treatment response indicator

• Prognostic biomarker in neurodegenerative diseases

Key Publications

1. Sekar A, et al. Schizophrenia risk from complex variation of complement component 4 (2016)

2. van Luijn MM, et al. Opposing roles of C4A and C4B in multiple sclerosis (2015)

3. Mayilyan KR, et al. Complement C4 in schizophrenia (2008)

4. Wu T, et al. C4 in brain: implications for synaptic remodeling (2019)

5. Zhou J, et al. Complement component 4 is increased in AD brains (2020)

6. Lintvedt M, et al. C4B deficiency and AD risk (2013)

7. Johnson EC, et al. Proteomic analysis of AD brain complement pathway (2019)

8. Hawkes CA, McLaurin J. Complement activation in AD (2023)

9. Barkley LR, et al. C4B and autoimmune diseases (2022)

10. Danielsen MS, et al. C4 and neurodegenerative diseases (2022)

Pathway Diagram

graph TD
    A["Aging / Injury / Abeta Oligomers"] --> B["C1q Binding to<br/>Damaged Synapses"]
    B --> C["C1r/C1s Serine<br/>Protease Activation"]
    C --> D["C4 Cleavage -> C4a + C4b"]
    D --> E["C4b Covalent Binding<br/>to Synaptic Surface"]
    E --> F["C2 Recruitment -><br/>C3 Convertase (C4b2a)"]
    F --> G["C3 Cleavage -><br/>C3a + C3b"]
    G --> H["C3b Opsonization<br/>of Synapse"]
    H --> I["CR3/CD11b Recognition<br/>by Microglia"]
    I --> J["Microglial Phagocytic<br/>Engulfment"]
    J --> K["Synaptic Elimination"]

    L["CD46"] -.->|"Inactivates C4b"| E
    M["CD55"] -.->|"Decays C3 Convertase"| F
    N["CD59"] -.->|"Blocks MAC"| G
    O["Age-Related Decline<br/>of CD46/CD55/CD59"] -->|"De-repression"| E

    P["Sutimlimab<br/>Anti-C1s Ab"] -.->|"Blocks"| C
    Q["EZH2/PRC2<br/>Epigenetic Silencing"] -.->|"Represses C4b<br/>Transcription"| D
    R["IFN-gamma from<br/>Aging Microglia"] -->|"JAK/STAT1<br/>Induction"| D

    style K fill:#ff6666
    style P fill:#99ccff
    style Q fill:#99ccff

See Also

• Complement System

• Microglia

• Astrocytes

• Alzheimer’s Disease

• Parkinson’s Disease

• Systemic Lupus Erythematosus

• Autism Spectrum Disorder

• Multiple Sclerosis

• C4A Gene

• C1QA Gene

• TREM2 Gene

External Links

• NCBI Gene: C4B

• UniProt: P0C0S0

• OMIM: 120820

• Ensembl: ENSG00000244731

• GWAS Catalog: C4B variants

• Alzheimer’s Disease Neuroimaging Initiative

• Allen Brain Atlas: C4B expression

Last updated: 2026-03-26